NHS and private routes to Mounjaro weight loss injections, explained

What SURMOUNT-1 actually found, and why NICE acted on it

The case for Mounjaro as a weight management injection rests primarily on SURMOUNT-1, a 72-week randomised trial published in the New England Journal of Medicine. Participants taking the 15 mg dose lost an average of around 20–21% of their body weight. To put that in context, earlier GLP-1 trials had rarely crossed 15%. The trial enrolled 2,539 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes. That is a large, well-characterised population, not a small proof-of-concept study.

NICE reviewed this evidence and, on 23 December 2024, published TA1026 recommending tirzepatide for NHS weight management. The committee's view, supported by indirect comparisons, was that tirzepatide produced greater average weight loss than semaglutide 2.4 mg, a finding later reinforced by the SURMOUNT-5 head-to-head trial in 2025. For anyone researching NHS Mounjaro weight loss injections, the short answer is: the evidence behind the recommendation is robust. The debate is about who gets access and when.

Mounjaro works by activating two gut-hormone receptors (GIP and GLP-1) simultaneously. This dual action reduces appetite, slows gastric emptying and improves how the body handles blood sugar. Treatment starts at 2.5 mg, with dose increases guided by the prescriber, usually in four-week steps. The aim is to reach the highest dose the patient tolerates well.

How NHS access to these weight loss injections is actually rolling out in 2025–2026

NICE TA1026 did not unlock Mounjaro for everyone who might benefit. NHS England set a phased rollout tied to BMI thresholds and the number of specific weight-related conditions a patient has. The five qualifying conditions are: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes.

From June 2025, the first cohort became eligible: adults with a BMI of 40 or above plus four or more of those five conditions. From 23 June 2026, Cohort 2 opened: BMI 35–39.9 plus four or more conditions. A further cohort, covering BMI 40-plus with three conditions, is expected around March 2027. Throughout, BMI thresholds are 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Even where someone meets the criteria, participation from their GP practice is optional, and every NHS patient must engage with wrap-around diet and activity support, access is not automatic. You can read a detailed breakdown on the NHS Mounjaro eligibility page.

For most people asking about weight loss injections and the NHS right now, the honest position is: the medicine is recommended, but the criteria are tight and the rollout is gradual. Private prescribing exists precisely for this gap. If you want to understand the practical NHS picture at practice level, NHS England's weight management injections guidance sets out the wraparound-care requirements in full.

Where to buy Mounjaro weight loss injections legally in the UK

Mounjaro is a prescription-only medicine. The only legal route to it is a valid prescription following clinical assessment, full stop. That assessment can happen through your GP (if your practice is participating and you meet the NHS cohort criteria), through an NHS specialist weight management service, or through a regulated private online pharmacy.

The risks of buying outside these routes are real and well-documented. The MHRA has made large seizures of counterfeit weight loss pens and raided an illicit UK manufacturing site producing fake tirzepatide pens in 2025. A quick way to check any online pharmacy before you hand over personal details: visit the GPhC register and search by name or registration number. Legitimate pharmacies are listed there; if they are not, walk away. This takes under a minute and removes most of the risk. Further detail on spotting unsafe sellers is on the guide to where you can buy Mounjaro injections.

The price of private Mounjaro varies by dose and provider. For context on what the market looks like and what to read into headline figures, the Mounjaro price comparison page breaks this down without the marketing noise. Stock availability also shifts, the Mounjaro stock checker can give you a current picture before you start a consultation. If you want to understand what the Mounjaro injection on the NHS looks like in practice, there is a dedicated page for that too.

Eligibility for private treatment and how clinical review works

Private prescribing follows the licensed indications: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, high cholesterol, type 2 diabetes, prediabetes or obstructive sleep apnoea. A BMI figure on its own never determines the outcome; a prescriber looks at your full health picture, any medicines you take, and any conditions that might affect suitability.

At a regulated pharmacy, that clinical review must happen before every order, not just the first. Photo-ID verification, live weight checks, GP notification in line with GPhC guidance, and evidence checks for dose increases are all part of a proper process. If you have been on treatment elsewhere and are considering switching, the guide to buying Mounjaro online covers what evidence transfer patients should expect to provide.

Mounjaro is a Black Triangle medicine, meaning it is subject to additional MHRA monitoring. Common side effects are gastrointestinal (nausea, loose stools, constipation, reflux) most noticeable in the early weeks or after a dose step-up, and generally settling with time. Anyone experiencing severe, persistent stomach pain that spreads to the back should get medical help promptly, given the MHRA's January 2026 Drug Safety Update on pancreatitis in GLP-1 medicines. Side effects and what to watch for in more detail are covered on the weight loss treatments overview.

If this has answered what you needed to know about the NHS and private landscape for Mounjaro weight loss injections, and you want to explore whether private treatment might suit you, the next step is a clinical conversation. Our prescribers at nume (sorry, at nume) review consultations the same working day; there is no waiting list, and the consultation itself is free. Start your free consultation when you are ready.